UNSPSC 51343118: Lamivudine sulfoxide

This classification denotes a reverse transcriptase inhibitor with the molecular formula C8H11N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L0EH965X85, chemically known as lamivudine sulfoxide, (3rs)-, but more generally known as lamivudine sulfoxide, which bears US NIH Compound Identifier 3081342. European Medicines Agency schedules lamivudine sulfoxide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08392MIG.

Most nations, for tariff purposes, schedule lamivudine sulfoxide under HS 29349990. SMILES: C1CN(C(=O)NC1N)[C@@H]2C[S+]([C@@H](O2)CO)[O-].

UNSPSC 51343118 Lamivudine sulfoxide, a Commodity code, appears in state and local procurement with little recent activity directly aligned to its nominal scope. The most-recent opportunities block contains two records: an Illinois Department of Public Health pharmaceutical warehouse piggyback contract awarded to Chartwell Rx LLC for Doxycycline Hyclate and Ciprofloxacin Hydrochloride (completed August 2026, $2,999,999.11 total award), and a Seminole County, Florida IFB for Naloxone and Safe Drug Deactivation Systems (posted June 2026). Neither opportunity directly involves lamivudine sulfoxide or related antiretroviral pharmaceuticals. The code shows no open solicitations and no identifiable pattern of state or local demand for the specific commodity named.

Geographic activity is limited to Illinois and Florida based on the two records provided, with no evidence of broader regional or multistate procurement activity under this code. Without open solicitations or active bids under UNSPSC 51343118, state and local demand for lamivudine sulfoxide cannot be characterized from recent opportunity data. Firms seeking to pursue this code should monitor state health departments, correctional agencies, and correctional health consortia for HIV treatment procurement, though current visibility is minimal.